A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
REGULATORY
CSIMC Approves Listing of 15 New APIs/19 Products Including Pfizer’s Xeljanz with Expected Peak Sales of 59.7 Billion Yen
The Central Social Insurance Medical Council (CSIMC), an advisory body to the health minister, approved the listing of 15 active pharmaceutical ingredients/19 products including Pfizer Japan’s oral rheumatoid arthritis treatment Xeljanz Tablets 5 mg (tofacitinib citrate) and Zeria Pharmaceutical’s functional…
To read the full story
REGULATORY
- LDP Kampo Caucus Chief Wary of Removing Insurance Coverage
November 10, 2025
- LDP Panel Backs Support for Drug Wholesalers in Economic Package
November 10, 2025
- Downstream Providers Decry Growing Negative Margins at Ryukaikon
November 10, 2025
- Category A Priority Drugs Kept in Separate-Handling Clause under Distribution Guidelines
November 10, 2025
- MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
November 7, 2025
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…